company background image

Vaccinex NasdaqCM:VCNX Stock Report

Last Price


Market Cap







06 Aug, 2022


Company Financials
VCNX fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health4/6

VCNX Stock Overview

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs.

Vaccinex Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vaccinex
Historical stock prices
Current Share PriceUS$1.03
52 Week HighUS$2.60
52 Week LowUS$0.90
1 Month Change-2.83%
3 Month Change-18.25%
1 Year Change-58.47%
3 Year Change-79.13%
5 Year Changen/a
Change since IPO-90.95%

Recent News & Updates

Shareholder Returns

VCNXUS BiotechsUS Market

Return vs Industry: VCNX underperformed the US Biotechs industry which returned -24.5% over the past year.

Return vs Market: VCNX underperformed the US Market which returned -12.8% over the past year.

Price Volatility

Is VCNX's price volatile compared to industry and market?
VCNX volatility
VCNX Average Weekly Movement9.2%
Biotechs Industry Average Movement12.9%
Market Average Movement7.9%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: VCNX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: VCNX's weekly volatility (9%) has been stable over the past year.

About the Company

200140Maurice Zauderer

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington’s disease, Alzheimer’s disease, osteosarcoma, and melanoma.

Vaccinex Fundamentals Summary

How do Vaccinex's earnings and revenue compare to its market cap?
VCNX fundamental statistics
Market CapUS$43.94m
Earnings (TTM)-US$20.40m
Revenue (TTM)US$50.00k


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VCNX income statement (TTM)
Cost of RevenueUS$14.61m
Gross Profit-US$14.56m
Other ExpensesUS$5.84m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)-0.48
Gross Margin-29,126.00%
Net Profit Margin-40,802.00%
Debt/Equity Ratio1.4%

How did VCNX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is VCNX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VCNX?

Other financial metrics that can be useful for relative valuation.

VCNX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue549.4x
Enterprise Value/EBITDA-1.3x
PEG Ration/a

Price to Book Ratio vs Peers

How does VCNX's PB Ratio compare to its peers?

VCNX PB Ratio vs Peers
The above table shows the PB ratio for VCNX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2.2x
ISR Isoray
CYCN Cyclerion Therapeutics
OTLC Oncotelic Therapeutics
MTEM Molecular Templates
VCNX Vaccinex

Price-To-Book vs Peers: VCNX is expensive based on its Price-To-Book Ratio (2.7x) compared to the peer average (2.2x).

Price to Earnings Ratio vs Industry

How does VCNX's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: VCNX is expensive based on its Price-To-Book Ratio (2.7x) compared to the US Biotechs industry average (1.8x)

Price to Book Ratio vs Fair Ratio

What is VCNX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VCNX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate VCNX's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of VCNX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VCNX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VCNX's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Vaccinex forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vaccinex has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Examine Vaccinex's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.

Past Performance

How has Vaccinex performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: VCNX is currently unprofitable.

Growing Profit Margin: VCNX is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: VCNX is unprofitable, but has reduced losses over the past 5 years at a rate of 1.1% per year.

Accelerating Growth: Unable to compare VCNX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VCNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (40.8%).

Return on Equity

High ROE: VCNX has a negative Return on Equity (-126.03%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Vaccinex's financial position?

Financial Health Score


Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: VCNX's short term assets ($17.8M) exceed its short term liabilities ($1.8M).

Long Term Liabilities: VCNX's short term assets ($17.8M) exceed its long term liabilities ($156.0K).

Debt to Equity History and Analysis

Debt Level: VCNX has more cash than its total debt.

Reducing Debt: VCNX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VCNX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: VCNX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 4.4% each year

Discover healthy companies


What is Vaccinex current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate VCNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VCNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VCNX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VCNX's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as VCNX has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Maurice Zauderer (76 yo)





Dr. Maurice Zauderer, Ph.D. Co-Founded Vaccinex, Inc. in April 2001 and also serves as its President and Chief Executive Officer since April 2001. Dr. Zauderer serves as Director of Vaccinex Inc. since Apr...

CEO Compensation Analysis

Compensation vs Market: Maurice's total compensation ($USD401.50K) is below average for companies of similar size in the US market ($USD767.72K).

Compensation vs Earnings: Maurice's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: VCNX's management team is seasoned and experienced (13.6 years average tenure).

Board Members

Experienced Board: VCNX's board of directors are seasoned and experienced ( 18.5 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 50%.

Top Shareholders

Company Information

Vaccinex, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Vaccinex, Inc.
  • Ticker: VCNX
  • Exchange: NasdaqCM
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$43.944m
  • Shares outstanding: 42.66m
  • Website:

Number of Employees


  • Vaccinex, Inc.
  • 1895 Mount Hope Avenue
  • Rochester
  • New York
  • 14620
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/06 00:00
End of Day Share Price2022/08/05 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.